Larimar Therapeutics financials
$3.14−0.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M | -$42.8M |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M | -$42.5M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-2.27 | $-1.32 | $-0.84 | $-1.37 | $-2.95 | $-3.57 |
| EBITDA | -$172.1M | -$90.6M | -$41.4M | -$36.2M | -$50.1M | -$42.6M |
| Operating cash flow | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M | -$42.2M |
| Free cash flow | -$113.3M | -$71.3M | -$33.6M | -$27.7M | -$42.4M | -$42.3M |
| Diluted shares | 72.9M | 61.3M | 43.9M | 25.8M | 17.2M | 11.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $85.4M | $33.2M | $26.7M | $26.8M | $70.1M | $68.1M |
| Short-term investments | $51.4M | $150.2M | $60.0M | $91.6M | — | $24.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M | $104.7M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M | $15.0M |
| Shareholders' equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M | $89.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology